Cargando…

The Role of Metabolic Dysfunction–Associated Fatty Liver Disease in Developing Chronic Kidney Disease: Longitudinal Cohort Study

BACKGROUND: The association between metabolic dysfunction–associated fatty liver disease (MAFLD) and chronic kidney disease (CKD) is unclear. OBJECTIVE: This longitudinal cohort study aimed to test whether MAFLD plays an important role in the development of CKD. METHODS: This cohort study included 4...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Suosu, Song, Jian, Xie, Yujie, Huang, Junzhang, Yang, Jianrong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JMIR Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196898/
https://www.ncbi.nlm.nih.gov/pubmed/37140958
http://dx.doi.org/10.2196/45050
_version_ 1785044443460534272
author Wei, Suosu
Song, Jian
Xie, Yujie
Huang, Junzhang
Yang, Jianrong
author_facet Wei, Suosu
Song, Jian
Xie, Yujie
Huang, Junzhang
Yang, Jianrong
author_sort Wei, Suosu
collection PubMed
description BACKGROUND: The association between metabolic dysfunction–associated fatty liver disease (MAFLD) and chronic kidney disease (CKD) is unclear. OBJECTIVE: This longitudinal cohort study aimed to test whether MAFLD plays an important role in the development of CKD. METHODS: This cohort study included 41,246 participants who had undergone 3 or more health examinations from 2008 to 2015 at the People’s Hospital of Guangxi Zhuang Autonomous Region, China. Participants were categorized into 2 groups according to whether they presented with or without MAFLD. The occurrence of new-onset CKD was stated as either an estimated glomerular filtration rate of <60 mL/min per 1.73 m(2) or a higher level of albuminuria during their follow-up appointment. The association between MAFLD and CKD was evaluated using a Cox regression method. RESULTS: Of the 41,246 participants, 11,860 (28.8%) were diagnosed with MAFLD. Over the course of the 14-year follow-up (median 10.0 years), 5347 (13%) participants experienced a new incident of CKD (135.73 per 10,000 person-years). MAFLD was discovered as an important risk factor for new incidents of CKD (hazard ratio 1.18, 95% CI 1.11-1.26) by using the multivariable Cox proportional hazard regression model. When stratified by gender, the adjusted hazard ratio for the incidence of CKD in men and women with MAFLD were 1.16 (95% CI 1.07-1.26) and 1.32 (95% CI 1.18-1.48), respectively. According to the subgroup analysis results, after adjusting for confounding factors, the MAFLD-related CKD risk was greater in men aged <60 years (P(interaction)=.001) and in those with combined dyslipidemia (P(interaction)=.02), but this relationship was not found in women (all P(interaction)>.05). CONCLUSIONS: MAFLD plays an important role in the development of new incidents of CKD in the long run. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2200058543; https://www.chictr.org.cn/showproj.html?proj=153109
format Online
Article
Text
id pubmed-10196898
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher JMIR Publications
record_format MEDLINE/PubMed
spelling pubmed-101968982023-05-20 The Role of Metabolic Dysfunction–Associated Fatty Liver Disease in Developing Chronic Kidney Disease: Longitudinal Cohort Study Wei, Suosu Song, Jian Xie, Yujie Huang, Junzhang Yang, Jianrong JMIR Public Health Surveill Original Paper BACKGROUND: The association between metabolic dysfunction–associated fatty liver disease (MAFLD) and chronic kidney disease (CKD) is unclear. OBJECTIVE: This longitudinal cohort study aimed to test whether MAFLD plays an important role in the development of CKD. METHODS: This cohort study included 41,246 participants who had undergone 3 or more health examinations from 2008 to 2015 at the People’s Hospital of Guangxi Zhuang Autonomous Region, China. Participants were categorized into 2 groups according to whether they presented with or without MAFLD. The occurrence of new-onset CKD was stated as either an estimated glomerular filtration rate of <60 mL/min per 1.73 m(2) or a higher level of albuminuria during their follow-up appointment. The association between MAFLD and CKD was evaluated using a Cox regression method. RESULTS: Of the 41,246 participants, 11,860 (28.8%) were diagnosed with MAFLD. Over the course of the 14-year follow-up (median 10.0 years), 5347 (13%) participants experienced a new incident of CKD (135.73 per 10,000 person-years). MAFLD was discovered as an important risk factor for new incidents of CKD (hazard ratio 1.18, 95% CI 1.11-1.26) by using the multivariable Cox proportional hazard regression model. When stratified by gender, the adjusted hazard ratio for the incidence of CKD in men and women with MAFLD were 1.16 (95% CI 1.07-1.26) and 1.32 (95% CI 1.18-1.48), respectively. According to the subgroup analysis results, after adjusting for confounding factors, the MAFLD-related CKD risk was greater in men aged <60 years (P(interaction)=.001) and in those with combined dyslipidemia (P(interaction)=.02), but this relationship was not found in women (all P(interaction)>.05). CONCLUSIONS: MAFLD plays an important role in the development of new incidents of CKD in the long run. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2200058543; https://www.chictr.org.cn/showproj.html?proj=153109 JMIR Publications 2023-05-04 /pmc/articles/PMC10196898/ /pubmed/37140958 http://dx.doi.org/10.2196/45050 Text en ©Suosu Wei, Jian Song, Yujie Xie, Junzhang Huang, Jianrong Yang. Originally published in JMIR Public Health and Surveillance (https://publichealth.jmir.org), 04.05.2023. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Public Health and Surveillance, is properly cited. The complete bibliographic information, a link to the original publication on https://publichealth.jmir.org, as well as this copyright and license information must be included.
spellingShingle Original Paper
Wei, Suosu
Song, Jian
Xie, Yujie
Huang, Junzhang
Yang, Jianrong
The Role of Metabolic Dysfunction–Associated Fatty Liver Disease in Developing Chronic Kidney Disease: Longitudinal Cohort Study
title The Role of Metabolic Dysfunction–Associated Fatty Liver Disease in Developing Chronic Kidney Disease: Longitudinal Cohort Study
title_full The Role of Metabolic Dysfunction–Associated Fatty Liver Disease in Developing Chronic Kidney Disease: Longitudinal Cohort Study
title_fullStr The Role of Metabolic Dysfunction–Associated Fatty Liver Disease in Developing Chronic Kidney Disease: Longitudinal Cohort Study
title_full_unstemmed The Role of Metabolic Dysfunction–Associated Fatty Liver Disease in Developing Chronic Kidney Disease: Longitudinal Cohort Study
title_short The Role of Metabolic Dysfunction–Associated Fatty Liver Disease in Developing Chronic Kidney Disease: Longitudinal Cohort Study
title_sort role of metabolic dysfunction–associated fatty liver disease in developing chronic kidney disease: longitudinal cohort study
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196898/
https://www.ncbi.nlm.nih.gov/pubmed/37140958
http://dx.doi.org/10.2196/45050
work_keys_str_mv AT weisuosu theroleofmetabolicdysfunctionassociatedfattyliverdiseaseindevelopingchronickidneydiseaselongitudinalcohortstudy
AT songjian theroleofmetabolicdysfunctionassociatedfattyliverdiseaseindevelopingchronickidneydiseaselongitudinalcohortstudy
AT xieyujie theroleofmetabolicdysfunctionassociatedfattyliverdiseaseindevelopingchronickidneydiseaselongitudinalcohortstudy
AT huangjunzhang theroleofmetabolicdysfunctionassociatedfattyliverdiseaseindevelopingchronickidneydiseaselongitudinalcohortstudy
AT yangjianrong theroleofmetabolicdysfunctionassociatedfattyliverdiseaseindevelopingchronickidneydiseaselongitudinalcohortstudy
AT weisuosu roleofmetabolicdysfunctionassociatedfattyliverdiseaseindevelopingchronickidneydiseaselongitudinalcohortstudy
AT songjian roleofmetabolicdysfunctionassociatedfattyliverdiseaseindevelopingchronickidneydiseaselongitudinalcohortstudy
AT xieyujie roleofmetabolicdysfunctionassociatedfattyliverdiseaseindevelopingchronickidneydiseaselongitudinalcohortstudy
AT huangjunzhang roleofmetabolicdysfunctionassociatedfattyliverdiseaseindevelopingchronickidneydiseaselongitudinalcohortstudy
AT yangjianrong roleofmetabolicdysfunctionassociatedfattyliverdiseaseindevelopingchronickidneydiseaselongitudinalcohortstudy